Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).
Reslizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).
Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
It is very uncertain whether inhaled corticosteroids plus standard care changes serious adverse events compared with standard care (with or without placebo) (very low certainty).
Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
Benralizumab 10 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Benralizumab 30 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).